<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02561767</url>
  </required_header>
  <id_info>
    <org_study_id>MSCs-KTx-DCD-150924</org_study_id>
    <nct_id>NCT02561767</nct_id>
  </id_info>
  <brief_title>Effect of BM-MSCs in DCD Kidney Transplantation</brief_title>
  <official_title>The Efficacy and Safety of Bone Marrow-derived Mesenchymal Stem Cells in Kidney Transplantation From Chinese Donation After Citizen Death (DCD): A Multi-center Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine the efficacy and safety of allogeneic bone marrow-derived
      mesenchymal stem cells in kidney transplantation from Chinese donation after citizen's death
      (DCD). A pair uremia patients receiving kidney grafts from a same donor are randomized into
      two groups: MSCs group and control group. Besides routine induction therapy (ATG or
      Basiliximab) and maintenance immunosuppressive drugs (low-dose Tacrolimus + MPA +
      prednisone), patients in MSCs group are administered MSCs treatment (1*10^6/kg). Allogeneic
      bone marrow-derived MSCs (1*10^6/kg) are given intravenously at day 0 (post renal reperfusion
      during surgery), day 7, day 14 and day 21. The renal allograft function, rejection,
      patient/graft survival and severe adverse events within 12 months post-transplant are
      monitored.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated glomerular filtration rate</measure>
    <time_frame>1 month</time_frame>
    <description>eGFR at one month post-transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of slow graft function</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of delayed graft function</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of normal renal function recovery</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to renal function recovery</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal graft survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute rejection</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate</measure>
    <time_frame>12 months</time_frame>
    <description>eGFR up to 12 months post-transplant</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Acute Kidney Tubular Necrosis</condition>
  <arm_group>
    <arm_group_label>MSCs group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogeneic bone marrow-derived mesenchymal stem cells (10^6/kg) from third party donors is intravenously given at day 0 (after renal artery reperfusion), day 7, day 14 and day 21.Induction therapy: ATG or Basiliximab; Maintenance therapy: low-dose Tacrolimus + mycophenolic acid + prednisone.
The third-party MSCs have no similar HLA alleles of kidney donors, and have no HLA alleles specific to preformed anti-HLA antibodies in recipients prior to KTx.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (saline) is intravenously given at day 0 (after renal artery reperfusion), day 7, day 14 and day 21. Induction therapy: ATG or Basiliximab; Maintenance therapy: low-dose Tacrolimus + mycophenolic acid + prednisone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>bone marrow-derived mesenchymal stem cells</intervention_name>
    <description>BM-MSCs is harvested from third-party health volunteer donors.</description>
    <arm_group_label>MSCs group</arm_group_label>
    <other_name>BM-MSCs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline as placebo of MSCs</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction therapy (ATG or Basiliximab)</intervention_name>
    <description>ATG, antithymocyte globulin; Basiliximab, anti-CD25 mAb. Recipients receive ATG or Basiliximab as induction therapy in both MSCs group and control group.</description>
    <arm_group_label>MSCs group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>ATG or Basiliximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maintenance therapy (Low-dose CNI + MPA + steroids)</intervention_name>
    <description>Maintenance immunosuppressive therapy consists of low-dose tacrolimus and mycophenolic acid and steroids. Recipients receive the same maintenance therapy in both MSCs group and control group.</description>
    <arm_group_label>MSCs group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Low-dose tacrolimus + Mycophenolic acid (MPA) + steroids</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Primary kidney transplantation

          2. Receiving induction therapy and combined immunosuppressive regimens (CNIs + MPA +
             steroids)

          3. Patient is willing and capable of giving written informed consent for study
             participation and able to participate in the study for 12 months

        Exclusion Criteria:

          1. Secondary kidney transplantation

          2. Combined or multi-organ transplantation

          3. Women who are pregnant, intend to become pregnant in the next 1 years, breastfeeding,
             or have a positive pregnancy test on enrollment or prior to study medication
             administration

          4. Panel reactive antibody (PRA)&gt;20%

          5. CDC crossmatch is positive

          6. Donors or recipients are known hepatitis C antibody-positive or polymerase chain
             reaction (PCR) positive for hepatitis C

          7. Donors or recipients are known hepatitis B surface antigen-positive or PCR positive
             for hepatitis B

          8. Donors or recipients are known human immunodeficiency virus (HIV) infection

          9. Patients with active infection

         10. Recipients with a history of substance abuse (drugs or alcohol) within the past 6
             months, or psychotic disorders that are not capable with adequate study follow-up.

         11. Patients with severe cardiovascular dysfunction

         12. WBC&lt;3*10^9/L or RBC &lt;5g/dL

         13. Highly allergic constitution or having severe history of allergies.

         14. Patients with active peptic ulcer disease, chronic diarrhea, or gastrointestinal
             problem affect absorption

         15. Patients with a history of cancer within the last 5 years

         16. Prisoner or patients compulsorily detained (involuntarily incarcerated) for treatment
             or either a psychiatric or physical (e.g. infectious disease) illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changxi Wang, M.D., Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Changxi Wang, M.D., Ph.D</last_name>
    <phone>86-20-87333428</phone>
    <email>wangchx@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Longshan Liu, M.D., Ph.D</last_name>
    <phone>86-20-87306082</phone>
    <email>liulshan@mail.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/23263506</url>
    <description>Previous publication</description>
  </link>
  <reference>
    <citation>Peng Y, Ke M, Xu L, Liu L, Chen X, Xia W, Li X, Chen Z, Ma J, Liao D, Li G, Fang J, Pan G, Xiang AP. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation. 2013 Jan 15;95(1):161-8. doi: 10.1097/TP.0b013e3182754c53. Erratum in: Transplantation. 2014 Mar 27;97(6):e37. Pan, Guanghui [added].</citation>
    <PMID>23263506</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2015</study_first_submitted>
  <study_first_submitted_qc>September 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2015</study_first_posted>
  <last_update_submitted>September 25, 2015</last_update_submitted>
  <last_update_submitted_qc>September 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Changxi Wang</investigator_full_name>
    <investigator_title>Director of Organ Transplant Center</investigator_title>
  </responsible_party>
  <keyword>kidney transplantation</keyword>
  <keyword>mesenchymal stem cell</keyword>
  <keyword>donation after citizen's death</keyword>
  <keyword>ischemia reperfusion injury</keyword>
  <keyword>renal function recovery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Kidney Tubular Necrosis, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

